Publications

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting

Ann Rheum Dis. 2021;80(9):1130-1136

Miyazaki Y,

Nakano K,

Nakayamada S,

Kubo S,

Inoue Y,

Fujino Y,

Tanaka Y.

Propensity score-based inverse probability of treatment weighting shows that efficacy may differ between tofacitinib and baricitinib. Miyazaki, et al. compared the efficacy and safety of the two JAK inhibitors in real-world clinical practice, after reduction to a minimum of the selection bias, using propensity score-based inverse probability of treatment weighting, and adjustment for confounding patient characteristics. They found that tofacitinib may be less effective in patients resistant to m...

Keywords:

• JAK,
• Baricitinib,
• Efficacy,
• Safety,
• Real-World

Real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia

Clin Rheumatol. 2021. Epub ahead of print doi: 10.1007/s10067-021-05853-x

Bird P,

Littlejohn G,

Butcher B,

Smith T,

O'Sullivan C,

Witcombe D,

Griffiths H.

Real-world evidence suggests that monotherapy and combination therapy tofacitinib is an effective intervention in RA with persistence and effectiveness comparable to bDMARDs. Despite recommendations from EULAR that bDMARDs and tsDMARDs be used in combination with csDMARDs for the treatment of RA, it is estimated that up to a third of patients take their medication as monotherapy.This post hoc analysis of data from the Australian OPAL study by Bird, et al. aimed to describe the real-world effecti...

Keywords:

• JAK,
• Tofacitinib,
• Efficacy,
• Real-World

Real-World Comparative Effectiveness and Safety of Tofacitinib and Baricitinib in Patients With Rheumatoid Arthritis

Arthritis Res Ther. 2021;23(1):197

Iwamoto N,

Sato S,

Kurushima S,

Michitsuji T,

Nishihata S,

Okamoto M,

Tsuji Y,

Endo Y,

Shimizu T,

Sumiyoshi R,

Suzuki T,

Okada A,

Koga T,

Kawashiri SY,

Fujikawa K,

Igawa T,

Aramaki T,

Ichinose K,

Tamai M,

Nakamura H,

Mizokami A,

Origuchi T,

Ueki Y,

Eguchi K,

Kawakami A.

In a real-world setting, tofacitinib and baricitinib have comparable continuing efficacies and safety profiles in patients with RA.It is important to determine the differences and similarities of JAK inhibitors in a real-world setting so that the optimal agent can be administered. However, until now, no published data of a direct comparison among these agents in RA have been available. With this in mind, Iwamoto, et al. compared the efficacy and safety of tofacitinib with those of baricitinib by...

Keywords:

• JAK,
• Baricitinib,
• Tofacitinib,
• Efficacy,
• Safety,
• Real-World

Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis

RMD Open. 2021;7(2):e001601.

Mori S,

Urata Y,

Yoshitama T,

Ueki Y.

Findings from a multicentre cohort study in Japan provide important information that is expected to aid in determining the position of tofacitinib in the treatment algorithm for RA.Mori S, et al. compared therapeutic outcomes, from real-world registries, at 12 months between tofacitinib-treated and tocilizumab-treated patients to clarify whether tofacitinib should only be considered as an option for patients who have either failed to respond to at least one bDMARD or are MTX-resistant/-intoleran...

Keywords:

• JAK,
• IL-6,
• Tofacitinib,
• Tocilizumab,
• Efficacy,
• Safety

Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study

Rheumatology (Oxford). 2021 Mar 22:keab294. Epub ahead of print. DOI: 10.1093/rheumatology/keab294

Desai RJ,

Pawar A,

Khosrow-Khavar F,

Weinblatt ME,

Kim SC

A population-based cohort study of 87,653 RA patients has found no evidence for an increased risk of venous thromboembolism (VTE) for tofacitinib, versus TNFis, in patients with RA.The introduction of JAKinibs, almost a decade ago, has provided an important oral option for the treatment of RA. However, in recent years, a safety concern, relating to incidence of VTE after treatment, has emerged. Consequently, both the US and European regulatory authorities now recommend caution for use of tofacit...

Keywords:

• JAK,
• Tofacitinib,
• Safety,
• Real-World

Estudo de Segurança Comparativa Pós-Aprovação de Tofacitinib e Fármacos Biológicos Antirreumáticos Modificadores de Doença: Resultados de 5 anos de um Registro de Artrite Reumatoide Sediado nos Estados Unidos

ACR Open Rheumatol. 2021 Feb 11.

Kremer JM,

Bingham CO 3rd,

Cappelli LC,

Greenberg JD,

Madsen AM,

Geier J,

Rivas JL,

Onofrei AM,

Barr CJ,

Pappas DA,

Litman HJ,

Dandreo KJ,

Shapiro AB,

Connell CA,

Kavanaugh A

Analysis from the US Corrona RA registry has provided the longest-term real-world safety data for a JAK inhibitor to date. The analysis showed that the cohorts had similar adverse events, except for higher herpes zoster rates for tofacitinib initiators vs bDMARDs.Kremer JM, et al. analysed adult patients with RA newly initiating tofacitinib, or a bDMARD, to compare incidence rates of MACE, SIEs, HZ, malignancies and death. VTE data were also collected prospectively and assessed descriptively thr...

Keywords:

• JAK,
• Tildrakizumab,
• Real-World

Qual Resultado Relatado pelo Paciente é o mais Importante para os Pacientes Reumatológicos para ser Rastreado Digitalmente? Um Estudo Longitudinal de Mundo-Real de ArthritisPower

Arthritis Res Ther. 2021;23(1):53.

Nowell WB,

Gavigan K,

Kannowski CL,

Cai Z,

Hunter T,

Venkatachalam S,

Birt J,

Workman J,

Curtis JR

Fatigue, physical function, pain, and morning joint stiffness are the most important PROs to track, according to the rheumatology patients who experience these symptoms. Increasingly used, alongside clinical measures, to track symptoms and assess disease activity over time, patient-reported outcomes (PROs) are also important indicators of quality of life and treatment effectiveness. To enable us to better understand which PROs patients with rheumatic and musculoskeletal disease consider most imp...

Keywords:

• PRO / QoL,
• Real-World

Eficácia Comparativa de Inibidor do Fator de Necrose Tumoral de Primeira Linha versus Biológico no Inibidor do Fator de Necrose Tumoral e Agentes Sintéticos Dirigidos em Pacientes com Artrite Reumatoide: Resultados de um Grande Estudo de Registro Americano

Ann Rheum Dis 2021;80:96–102.

Pappas DA,

St John G,

Etzel CJ,

Fiore S,

Blachley T,

Kimura T,

Punekar R,

Emeanuru K,

Choi J,

Boklage S,

Kremer JM

RA treatment guidelines recommend a treat-to-target approach guided by disease stage and treatment history, yet the optimal sequence of different treatment modalities has not been established. Data from Corrona – were used to evaluate the comparative effectiveness of TNFi versus non-TNFi bDMARDs and tsDMARDs as first-line treatment following csDMARD failure. Results support RA guidelines recommending individualised care based on clinical judgement and consideration of patient preference.The stud...

Keywords:

• Real-World

Incidência Baseada em Idade (<65 vs ≥65 anos) de Infecções e Infecções Graves com Tofacitinib versus DMARDs biológicos nos Ensaios Clínicos em Artrite Reumatoide nos EUA e no Registro Corrona RA

Ann Rheum Dis 2020; DOI: 10.1136/annrheumdis-2020-218992

Winthrop KL,

Citera G,

Gold D,

Henrohn D,

Connell CA,

Shapiro AB,

Shi H,

Onofrei AM,

Pappas DA,

Schulze-Koops H

Reports from clinical trials and the US Corrona RA registry showed that serious infection event (SIE) incidence was higher in older versus younger patients with RA receiving 10 mg BID of TOF and ADA, however, SIE risk was similar between age groups with TOF 5 mg BID and ADA.Data were collected from Phase II–IV tofacitinib studies, and the US Corrona RA registry. The clinical data set evaluated patients receiving TOF 5 and 10 mg BID versus TNFi (ADA/ETN) in RA patients aged ≥50 years. The EMA rec...

Keywords:

• JAK,
• Tofacitinib,
• Safety,
• Real-World,
• Infections

Incidência de Eventos Tromboembólicos Arteriais e Venosos Reportados nos Programas de Desenvolvimento de Tofacitinib em Artrite Reumatoide, Psoríase e Artrite Psoriática e de Dados de Mundo Real

Annals of the Rheumatic Diseases 05 August 2020 2020 Nov;79(11):1400-1413. doi: 10.1136/annrheumdis-2019-216761. Epub 2020 Aug 5.

Mease P,

Charles-Schoeman C,

Cohen S,

Fallon L,

Woolcott J,

Yun H,

Kremer J,

Greenberg J,

Malley W,

Onofrei A,

Kanik KS,

Graham D,

Wang C,

Connell C,

Valdez H,

Hauben M,

Hung E,

Madsen A,

Jones TV,

Curtis JR

Concerns surrounding increased rates of PE and cardiovascular associated deaths has led to black box warnings when prescribing JAK inhibitors. As such, ongoing investigations regarding cardiovascular and VTE event risks in JAK inhibitor therapies, both clinical and real-world, are vital. Mease and colleagues consider data from clinical tofacitinib development programmes, and the ongoing real-data study A3921133. Conclusions from data analysis state that those with pre-existing cardiovascular and...

Keywords:

• JAK,
• Tofacitinib,
• Safety